Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Kidney (Renal Cell)

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 676 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio (~338 per treatment arm) at approximately 150 sites.
Kidney (Renal Cell)
III
Beckermann, Kathryn
NCT03937219
VICCURO1938

A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma

Multiple Cancer Types

The purpose of this study is to determine whether the combination of nivolumab and ipilimumab is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced the partial or entire removal of a kidney
Kidney (Renal Cell), Urologic
III
Beckermann, Kathryn
NCT03138512
VICCURO1953

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: